Recently, diminazene aceturate (DIZE), another US Food and Drug Administration-listed small molecule used as an antitrypanosomal drug, has been shown to exert off-target effects of activating ACE2. 16 We have recently demonstrated that DIZE treatment renders cardioprotective effects and improves angiogenic progenitor cell functions in rat model of pulmonary hypertension. 17 This complied with the fact Abstract-Angiotensin-converting enzyme 2 (ACE2) plays a critical role against myocardial infarction (MI). We hypothesized that activation of intrinsic ACE2 would be protective against ischemia-induced cardiac pathophysiology. 
T he renin-angiotensin system (RAS) plays a critical role in maintaining cardiovascular homeostasis. Angiotensinconverting enzyme 2 (ACE2) metabolizes angiotensin II (AngII) into the heptapeptide angiotensin-(1-7) (Ang- [1] [2] [3] [4] [5] [6] [7] ), 1, 2 thereby maintaining a balance between the deleterious axis (ACE/AngII/angiotensin type 1 receptor [AT1R]) and the vasoprotective axis (ACE2/Ang-(1-7)/Mas receptor [MasR] ) of the RAS. ACE inhibitors and angiotensin receptor blockers are leading pharmacotherapeutic interventions for cardiovascular diseases. [3] [4] [5] It has been demonstrated that the use of these agents to inhibit the deleterious axis of the RAS leads to an upregulation of ACE2. 6 ACE2 modulates cardiac function and could be a potential therapeutic target for cardiovascular diseases, on the basis of the following evidences: (1) ACE2 and Ang-(1-7) levels are increased as a compensatory mechanism in the heart after myocardial infarction (MI) in both humans and rats [7] [8] [9] ; (2) we and others have demonstrated that cardiac overexpression of ACE2 renders protection against ischemia-induced cardiac pathophysiology 10, 11 ; (3) overexpression of Ang-(1-7) protects the heart from the ischemic-induced cardiac dysfunction 12 ; (4) we have previously demonstrated that a small molecule, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), possessing the potential to activate ACE2, prevents cardiac remodeling in spontaneously hypertensive rats. 13 Collectively, these findings have led several groups to propose that administration of recombinant ACE2 could be a potential therapeutic strategies for the treatment of heart failure. 14, 15 that current standard treatments for MI cannot efficiently improve cardiac function and prevent further damage to the myocardium. We decided to evaluate the effects of DIZE on ischemic-induced cardiac pathophysiology. Our observations demonstrate that DIZE treatment prevents MI-induced cardiac pathophysiology, thus providing us an opportunity to explore the therapeutic potential of this compound in ischemic heart disease and heart failure.
Material and Methods
All experimental protocols are presented in the Methods in the online-only Data Supplement.
Results

DIZE Treatment Prevents the MI-Induced Left Ventricular Dysfunction, and C-16 Abolishes the Protective Effects of DIZE
MI caused a 62% reduction in fractional shortening ( Figure 1A ) and a 27% increase in ventricular hypertrophy ( Figure 1B ), which were significantly prevented by DIZE treatment. Measurement of cardiac hemodynamic functions in MI animals revealed higher left ventricular end diastolic pressure and decreased dP/dt max and dP/dt min compared with normal and DIZE controls, which were restored by DIZE treatment ( Figure 1C-1E ). We had hypothesized that these beneficial effects of DIZE are associated with the activation of endogenous cardiac ACE2. Therefore, we coadministered C-16, a selective ACE2 inhibitor, 17 along with DIZE. Four weeks of cotreatment with C-16 abolished the improvements in cardiac function produced by DIZE ( Figure 1A-1E ). In contrast to these beneficial effects on cardiac pathophysiology, DIZE treatment did not alter systolic blood pressure ( Figure 1F ).
DIZE Treatment Alters Cardiac RAS Levels
mRNA levels of ACE and ACE2 and protein levels of AT1R and MasR were measured to determine whether DIZE treatment shifts the balance from deleterious to vasoprotective axis of the RAS. Cardiac ACE mRNA increased by 2-fold, whereas ACE2 mRNA decreased 2-fold in MI animals ( Figure 2A and 2B). DIZE treatment reduced ACE mRNA and significantly elevated ACE2 mRNA in the MI animals. As a result, the ratio of the mRNA levels of ACE2/ACE was 2-fold higher in DIZE-treated MI hearts ( Figure 2C ). MI induced 2-fold increase in ACE activity, although this activity in DIZE-treated MI hearts was not significantly different from the control and DIZE-treated hearts ( Figure 2D ). In contrast, ACE2 activity was modestly decreased in the periinfarct area of the MI hearts, and DIZE treatment resulted in 2.5-fold increase in this activity ( Figure 2E ). Plasma ACE2 activity was slightly lowered in MI animals and significantly increased by DIZE treatment, which was abolished by C-16 ( Figure 2F ). Moreover, Western blot analysis demonstrated a 1.9-fold increase in AT1R protein levels ( Figure 2G ) and a moderate increase in MasR ( Figure 2H ) in the MI group. DIZE treatment significantly inhibited the increase in AT1R. These changes induced by DIZE were blocked by treatment 
DIZE Treatment Increases Numbers of Cardiac Progenitor Cells and Circulating Endothelial Progenitor Cells
Our next objective was to determine whether the reparative capacities of DIZE are because of its effects on progenitor cells. Thus, we determined the levels of circulating endothelial progenitor cells (EPCs) and Islet-1 (a marker for cardiac progenitor cells [CPCs] ). We observed a 2-fold increase in the CPCs in the peri-infarct region of the DIZE-treated ischemic heart ( Figure 3A and 3B). This increase in the number of CPCs suggests a higher regenerative potential in the hearts from DIZE-treated animals. Moreover, the number of circulating EPCs was also increased by 48% in the DIZE-treated animals over that observed in the MI group ( Figure 3C ). Cotreatment of DIZE animals with C-16 abolished both increases in the CPCs and in the EPCs.
DIZE Treatment Decreases Infiltration of Macrophages in the Peri-Infarct Area of the Heart and Modulates Proinflammatory Cytokines
Infiltration of macrophage in the peri-infarct area of the heart is associated with MI. 18 Thus, we examined whether DIZE treatment would influence this process. DIZE treatment Figure 4 , top panel). Western blot analysis showed that CD68 immunoreactivity in MI hearts was increased by 46%, which was completely attenuated by DIZE treatment ( Figure 4A and 4B). Interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) mRNA levels were examined next to determine whether the beneficial effects of DIZE on cardiac hemodynamic were associated with changes in the proinflammatory cytokines. As expected, MI resulted in 2.5-and 3-fold increases in IL-1β and TNF-α, respectively ( Figure 4C and 4D) . DIZE treatment alone did not affect these cytokines in control animals. However, DIZE treatment in the MI animals prevented the increase in these cytokines, which further supported the anti-inflammatory effects of DIZE. C-16 blocked all the anti-inflammatory effects of DIZE (Figure 4 ).
DIZE Treatment Decreases Infarct Area and MI-Induced Apoptosis
DIZE treatment decreased the infarct size by 50% ( Figure  S1A in the online-only Data Supplement). Next, we examined whether DIZE exerts antiapoptotic effects in response to ischemia. Heart sections of the MI group showed 6-fold increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, which was prevented by DIZE treatment ( Figure S1B ). C-16 treatment abolished all the effects produced by DIZE ( Figure S1 ).
DIZE Treatment Prevents the MI-Induced Loss of Capillary Density
A significant reduction (1-fold) in capillary density was observed in MI hearts. DIZE treatment alone did not alter capillary density; however, DIZE treatment in the MI animals significantly prevented the decrease in the capillary density of the MI group ( Figure S2 ).
Discussion
Our study is significant in that it provides evidence that DIZE, an ACE2 activator offers impressive protection against MI by preserving fractional shortening, attenuating the increase in LVEDP, preventing the dysfunctional changes in dP/dt, and decreasing infarct size and apoptosis. This treatment also modulates the RAS in a positive manner, reduces inflammatory processes, and increases the engraftment of CPCs and circulating EPCs. All these beneficial effects were blocked by C-16.
The imbalance in the RAS as a result of an increase in the vasodeleterious (ACE/AngII/AT1R) axis and a decrease in the vasoprotective (ACE2/Ang-(1-7)/MasR) axis has been proposed to be critical in the development and establishment of cardiac pathophysiology. 19, 20 ACE2 expression is upregulated at the beginning of the MI as a compensatory mechanism 8 and then significantly decreased at heart failure stage. 21 Because DIZE is administered before the injury is induced, it protects heart function and thus prevents the ACE2 downregulation. It is also possible that DIZE modulates ACE2 expression and acts in a positive feedback manner because DIZE has been found to be able to bind DNA. 22 Thus, we hypothesize that restoring this imbalance by the activation of endogenous ACE2 could provide protection against cardiac damage. This study provides evidence in support of this concept and confirms the protective role of the vasoprotective axis because all the dysfunctional and pathological parameters were prevented by the ACE2 activator.
It has been shown that ACE2 overexpression in the human umbilical vein endothelial cells leads to an increase in tube formation and can promote endothelial cell migration in vitro, and ACE2 can promote capillary formation and neovessel maturation in vivo. 23, 24 DIZE, as an ACE2 activator, may also promote angiogenesis and exert its effects via Ang-(1-7). Ang-(1-7) also has been shown to directly act on hematopoietic progenitor cells and modulate their function. 25, 26 In the present study, DIZE causes an increase in CPCs homing to the peri-infarct area of the ischemic heart, increases circulating EPCs, and restores capillary density, all of which are correlated with an improvement of cardiac function. Our study and others indicate that the ACE2/Ang-(1-7)/MasR axis induces mechanisms that are pivotal for regenerative therapy, and further studies on the signaling pathways activated by DIZE in progenitor cells are warranted.
Elevated levels of proinflammatory cytokines, such as IL-1β and TNF-α, contribute to the development and progression of ischemic injury. 27, 28 The ACE2/Ang-(1-7)/MasR axis possesses an anti-inflammatory role. 29 Our observation that DIZE prevents increases in proinflammatory cytokines, and macrophage cells further supports the importance of this compound in influencing many pathological events, directly and indirectly. This is supported by our previous observations that overexpression of Ang-(1-7) and DIZE treatment decreases pulmonary proinflammatory cytokines in models of lung disease. 17, 30 In summary, our study illustrates that DIZE treatment preserves cardiac function and attenuates cardiac remodeling post-MI. The beneficial effects of DIZE may be a result of preventing the imbalance of the RAS observed post-MI, subsequently modulating various proinflammatory cytokines associated with MI injury, decreasing the infiltration of macrophages associated with cardiac ischemia, and increasing the homing of CPCs and mobilizing EPCs.
Finally, it is pertinent to point out that we have used DIZE as a compound to test this proof of concept. DIZE has been shown to exert toxic effects in some studies [31] [32] [33] and may not be the pharmacodynamically ideal molecule for translational studies. Nonetheless, the study is relevant in that it provides evidence that the chemical structure resides in DIZE has the 
Perspectives
Recently, Oudit and Penninger 14 have suggested that recombinant ACE2 can be used as a novel therapy for heart failure. However, the application of recombinant ACE2 protein for MI is limited by its peptide nature and possible metabolic degradation if administrated orally. The use of synthetic small molecules, such as DIZE, or other compounds that are ACE2 activators, could circumvent these issues. Thus, current observations support the concept that targeting of the cardiac ACE2/Ang-(1-7)/MasR axis using a small molecule could hold novel therapeutic strategy in the treatment of MI and its associated complications. 
Supplement Methods and Data
Material and Methods
Myocardial Infarction
Eight week old Sprague Dawley rats were divided into five experimental groups: 1) control (N=9); 2) DIZE (N=9); 3) MI (N=12); 4) MI+DIZE (N=12); and 5) MI+DIZE +C-16 (N=6). MI surgery was performed as described previously. 1 Briefly, the proximal left anterior descending coronary artery was ligated (CAL) using a 7-0 polypropylene suture. Successful cessation of coronary blood flow was confirmed by elevation of the ST segment on electrocardiogram and cyanosis of anterior LV wall. DIZE (15mg/kg, s.c.) was initiated two days before CAL surgery and continued throughout the four-week period. For the ACE2 inhibition study, compound 16 (C-16), a selective ACE2 inhibitor, was given (25mg/kg, s.c.) at same time with DIZE treatment, which was selected based on our published report. All animals were housed in a temperature-controlled room (25 ± 1°C) and were maintained on a 12:12-hour light:dark cycle with free access to water and food. All procedures involving experimental animals were approved by the Institutional Animal Care and Use Committee at the University of Florida and complied with National Institutes of Health guidelines.
Echocardiography
Cardiac function was assessed by echocardiography immediately before sacrifice, four weeks after the CAL surgery. Echocardiography was performed using a GE vivid7 ultrasound machine with a 12-Hz transducer (GE Healthcare, NJ, USA). Rats were anesthetized with the 2% isoflurane-oxygen mixture during the assessment. M-mode echocardiography was performed by using a parasternal short-axis view at the level of the papillary muscles. All measurements were based on the average of three consecutive cardiac cycles. LV internal diameter at end diastole (LVIDd) and end systole (LVIDs) were obtained. The fractional shortening was calculated according to the formulae: FS = [(LVIDd-LVIDs)/LVIDd] × 100
Hemodynamic Measurements
Cardiac function was also assessed by Millar catheterization four weeks after the CAL surgery. Rats were anesthetized with the 2% isoflurane-oxygen mixture, placed in supine position and the body temperature was maintained at 37 o C using a heated pad. The left ventricular function was measured by Millar catheterization by cannulating the right carotid artery and threading the catheter into the left ventricle. The catheter was interfaced to a PowerLab (ADInstruments, Colorado Springs, CO, USA) signal transduction unit. Data were analyzed using the Chart program supplied along with the PowerLab system. The parameters measured included systolic blood pressure (SBP), heart rate (HR), left ventricular end diastolic pressure (LVEDP), and maximal positive and negative rate of rise of the left ventricular pressure (dP/dt max and dP/dt min ).
Histological Analysis
Following the hemodynamic measurement, under deep anesthesia and laparotomy, hearts were collected. The ventricles were separated from atria and rinsed in 1x PBS, weighed, and cut into 3 three different sections made perpendicular to the long axis. The basal and apex section was snap frozen in liquid nitrogen and stored at -80°C for subsequent quantitative real-time PCR measurements. The middle section was used to measure the infarct size and cardiac remodeling. Ventricular sections were stained with Picro-Sirius Red to measure infarct size. 1 The midventricular section provides adequate estimation of total LV infarct size. 3 Total infarct size was calculated as a fraction of the left ventricular circumference. 4 Cardiac remodeling was assessed by determining ventricular hypertrophy, which was calculated by normalizing the wet weights of rat heart ventricles to the tibia length.
Apoptosis Assay
Apoptosis was determined using the Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (TMR red In Situ Cell Death Detection Kit) according to the manufacturer's protocol (Roche Diagnostics, Indianapolis, IN). Nuclei were labeled with 4′,6-diamidino-2-phenylindole(DAPI). For each slide, five different fields were evaluated at high magnification (×400). The number of the apoptotic nuclei (red fluorescence) was counted using ImageJ.
Capillary vessel density
Cross section of the heart ventricles were stained with Lectin GSI (Sigma-Aldrich Chemie©, Zwijndrecht, The Netherlands), as previously described. 5 Sections of 5μm thickness were deparaffinized and rehydrated. The sections were incubated overnight with the biotinylated Lectin GSI (1:250) at room temperature. The next day sections were rinsed, incubated with Sterpt AV Alexa 594 conjugated secondary antibody at room temperature for 1 h, and mounted with anti-fade mounting medium (Vectashield, Vector Laboratories). Since Lectins stain not only capillaries but also other vessels, a size criterion of 10μm was used to exclude small arterioles and venules. Six randomly selected fields in the viable LV free wall were photographed and analyzed in Image J software. Capillary density was calculated as the number of capillaries per tissue area in the viable LV wall.
ACE and ACE2 Activity in cardiac tissue and plasma
Plasma was diluted in ACE/ACE2 buffer [1M NaCl, 75mM Tris-HCl, and 0.5μM ZnCl2, at pH 7.4] at 1:10 ratio, as well as cardiac tissue (from the peri-infarct region of the LV), were homogenized in ACE/ACE2 buffer. All assays were performed in triplicate in ACE/ACE2 buffer. Ten nM ACE or ACE2 enzyme was used as positive controls. Human recombinant ACE Enzymatic activity was measured in a total volume of 100μL using a fluorescence plate reader (Synergy HT, Biotek, USA) at an excitation wavelength of 320nm and emission wavelength of 405nm as described previously. 6 All assays were performed at least in triplicate and samples were read at 37°C for 4h immediately after the addition of fluorogenic peptide substrate.
Western Blot
